Services on Demand
On-line version ISSN 1806-4841
An. Bras. Dermatol. vol.80 no.5 Rio de Janeiro Sept./Oct. 2005
CLINICAL, EPIDEMIOLOGICAL, LABORATORY AND THERAPEUTIC INVESTIGATION
Prevalence of cutaneous findings in systemic sclerosis patients - Experience of a teaching hospital*
Fernanda GuidolinI; Letícia EsmanhottoII; Carlos Eduardo MagroIII; Marilia Barreto SilvaIV; Thelma L. SkareIV
ISecond-year resident. Service of
Rheumatology, Hospital Universitário Evangélico de Curitiba (HUEC) - Curitiba
IIFirst-year resident. Service of Rheumatology, Hospital Universitário Evangélico de Curitiba (HUEC) - Curitiba (PR), Brazil
IIIM.D. Service of Rheumatology, Hospital Universitário Evangélico de Curitiba (HUEC) - Curitiba (PR), Brazil
IVAssistant Professor of Rheumatology. Medical Course, Faculdade Evangélica do Paraná - Curitiba (PR), Brazil
BACKGROUND: Systemic sclerosis or scleroderma
is a rare collagen disease presenting several cutaneous manifestations.
OBJECTIVE: To study the prevalence of cutaneous manifestations in systemic sclerosis and its subtypes (limited form, diffuse form and overlap syndrome).
METHODS: We studied 32 patients with scleroderma (20 with the limited form; 8 with the diffuse form and 4 with overlap syndrome) considering skin sclerosis, Raynaud's phenomenon, digital scars, telangiectasia, leucomelanoderma (pigmentary changes), microstomy, calcinosis and pruritus.
RESULTS: We found skin sclerosis and Raynaud's phenomenon in 100% of patients, digital scars in 65.6%, telangiectasia in 43.7%, pigmentary changes in 43.7%, microstomy in 31.25%, pruritus in 28.1% and calcinosis in 12.5%. No statistically significant differences were observed in the limited and diffuse forms of scleroderma (p = 1.0 for digital scars; p = 0.69 for teleangiectasis; p = 0.22 for microstomy; p = 1.0 for calcinosis and pruritus). The overlap syndrome was not different from the isolated forms (limited and diffuse) of systemic sclerosis.
CONCLUSION: The most common skin manifestations in scleroderma are skin sclerosis and Raynaud's phenomenon and calcinosis is the rarest. The other cutaneous manifestations presented similar frequency in all subtypes of scleroderma.
Keywords: Mixed connective tissue disease; Scleroderma, diffuse; Scleroderma, limited; Scleroderma, systemic.
Systemic scleroderma is a collagen disease that prevails in women and has a large number of cutaneous findings that should be well recognized by clinicians that manage this condition.1 It may present as an exclusively cutaneous (limited form) or systemic (SS) disease, which may be divided into limited form, when the skin thickens only in the extremities (face and "gloves and boots" type distribution), and generalized or diffuse form, when if affects the whole body.1,2 Exclusively visceral involvement (scleroderma sine scleroderma) is extremely rare.3,4 Sometimes SS may present with other connective tissue conditions, and is then called overlapping or mixed syndrome.1
In the systemic forms of the disease, skin sclerosis, which initially affects hands, may begin with an edematous aspect. In the well-established disease, it tends to have induration and, after some time, it may or may not develop into an atrophic form.1
These infiltrative changes are associated with pigmentary changes, pruritus, telangiectasia, calcinosis and ulcerative and scarring phenomena secondary to ischemia due to Raynaud's syndrome. Microstomy is a finding secondary to cutaneous face infiltration and causes perioral folds, contributing to the typical aspect of SS patients.1,2
The present study was performed with the objective of studying the prevalence of skin manifestations in the local population with SS, and of comparing findings between the limited, diffuse and overlapping forms.
PATIENTS AND METHODS
We studied all patients with SS (limited and diffuse forms, and overlapping syndrome with a scleroderma component) seen at the Rheumatology Outpatient Clinic of Hospital Universitário Evangélico de Curitiba during the year of 2003. The sample comprised 32 patients, 20 of which with the limited form, eight with the diffuse form and four with overlapping syndrome.
After signing the informed consent form, patients answered a questionnaire and were submitted to a physical examination regarding the most common cutaneous manifestations of the disease. The manifestations registered were: presence of Raynaud's phenomenon (Figure 1), history of digital pulp ulcerations and current or past itching crises. The physical examination aimed to show digital scars, telangiectasia (Figure 2), pigmentary changes (Figure 3), calcinosis (Figure 4) and microstomy (Figure 5). All patients whose oral opening was less than three middle fingers of the right hand were considered as having microstomy. Calcinosis was radiologically confirmed for all subjects.
Moreover, all patients were submitted to modified Rodnan skin score (MRSS), which consists of the sum total of scoring 17 anatomical sites, graded as 0 = normal skin; 1 = mild thickening (skin is thickened, but can still be pinched); 2 = moderate thickening (skin is thickened and cannot be pinched, but is not completely adhered to deep planes, allows light sliding); 3 = intense thickening (very thickened skin, cannot be pinched, adhered to deep planes, does not allow sliding).5
Only the individuals with complaints of intense itching followed by fast progression of skin thickening, which is attributed to mastocyte degranulation, were considered as patients with pruritus.6-8
Data were submitted to statistical analysis using the Prism (Graphpad, version 2.0) software; descriptive studies and the Fisher test were used for the comparative analysis between samples with discrete data, and the Kruskal-Wallis test was applied to continuous data. The level of significance adopted was 5%.
Out of 32 patients studied, there were 31 women, and one man. Age ranged from 22 to 67 years, with a mean of 47.11 ± 11.99 years. The demographic features of the three subgroups studied are in table 1.
All patients had Raynaud's phenomenon and its onset ranged from zero to 13 years prior to diagnosis of SS. In the limited form, the mean time for developing Raynaud's before diagnosis was 2.1 ± 3.44 years; in the diffuse form, 0.62 ± 1.40 years, and in the overlap syndrome, 3.2 ± 2.50 years (p = 0.152).
Involvement of hands was present in all patients as induration, except for one patient who had the edematous form.
As to other cutaneous findings, their prevalence in the scleroderma population as a whole was: digital scars in 21 patients (65.6%), telangiectasia in 14 (43.7%), pigmentary changes in 14 (43.7%), microstomy in 10 (31.25%), pruritus in nine (28.1%) and calcinosis in four (12.5%). These data are presented in graph 1.
The modified Rodnan skin score in the three forms represented a mean of 16.10 ± 6.56 in the limited form; 24.0 ± 5.97 in the diffuse form and 18.0 ± 3.16 in the overlapping syndrome, p = 0.030. The comparison of this variable in the different SS subsets showed a p = 0.02 between the diffuse and limited forms; p = 0.279 between the diffuse and overlapping forms and p = 0.59 between the overlapping and limited forms.
SS is a relatively rare disease, but stands out for the variety of cutaneous findings that assist in making diagnosis.
In the population studied, patients with diffuse SS had a shorter period of disease than those with other forms, a fact that can be easily understood, given that in this form the higher aggressiveness of the disease makes patients seek doctors sooner.
There was skin sclerosis in all patients and it was more severe in the diffuse form than in the limited one, which is translated as a higher modified Rodnan skin score. As a matter of fact, this component relates to poorer prognosis regarding patient survival.9
Raynaud's phenomenon was present in all patients; this is a very important finding since it shows that its absence makes the diagnosis of SS less likely. The high frequency of Raynaud's phenomenon in SS is acknowledged in the literature, with a prevalence ranging between 90 and 99%,1,10 moreover, it is the initial complaint of 70% of patients.11 According to Seibold, its absence is more frequently observed in male patients,12 a fact that cannot be appreciated in this sample composed of only one man.
The interval between the onset of Raynaud's phenomenon and diagnosis of SS was shorter in patients with the diffuse form, although the data did not show statistical significance.
A study performed with 63 patients showed a prevalence of 46% of digital scars.10 In the sample studied, the high prevalence of digital scars (65.6%) strengthens the importance and severity of Raynaud's phenomenon in these patients, given these scars result from micro infarctions in finger pulps.11
All other cutaneous manifestations studied, such as pigmentary changes, telangiectasia, microstomy, pruritus and calcinosis, were similarly observed in the different types of disease in the population studied, and the first two followed Raynaud's phenomenon and digital scars in prevalence. Akenson et al. had already observed similarity in the distribution of calcinosis, Raynaud's phenomenon and telangiectasia in the diffuse and limited forms of SS.13
Tager et al. showed a lower prevalence of telangiectasia (33%) and higher prevalence of calcinosis (19%) in their study, than those found in the present study.10 This may be explained by the ethnic and/or environmental differences of the populations analyzed, given that the authors only studied Black individuals in Southern Africa with a high rate of exposure to silica.
In conclusion, it could be emphasized that the most common cutaneous manifestations of SS in the present population, in addition to skin sclerosis itself, was Raynaud's phenomenon and digital scars. These findings should lead to inclusion of SS in the differential etiological diagnosis. Identifying associated cutaneous findings may help making presumptive diagnoses, even if they do not help distinguishing among the three subtypes. q
1. Wigley FM. Systemic Sclerosis: clinical features. In Klippel JH, Crofford JL, Stone JH, Weyand CM. Primer on rheumatic diseases. Atlanta: Arthritis Foundation; 2001. p.357-63. [ Links ]
2. Rocco VK, Hurd E. Scleroderma and scleroderma like disorders. Sem Arthritis Rheum. 1986; 16:22-69. [ Links ]
3. Wigley FM. Systemic Sclerosis: clinical features. In Klippel JH, Dieppe PA. Rheumatology. London: Mosby; 1998. p.S-9:1-14. [ Links ]
4. Panicheewa S, Chitrabamrung S, Verasertniyon O, Vanichaphantu M, Kraisit SO, Chiewsilp P, et al. Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol. 1991; 10:124-9. [ Links ]
5. Akenson A, Fiori G, Krieg T, Van den Hoogen FHJ, Seibold JR. The assesment of the patient with systemic sclerosis. The assesment of skin, joint, tendon and muscle envolvement. Clin Exp Rheumatol. 2003; 21: S5-S8. [ Links ]
6. Falanga V, Soter NA, Altman RD, Kerdel FA. Elevated plasma histamine levels in systemic sclerosis. Arch Dermatol. 1990; 126:336-8. [ Links ]
7. Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum. 1990; 33 :1702-9. [ Links ]
8. Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998; 138:399-406. [ Links ]
9. Geirsson AJ, Wolheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheuma Dis. 2001; 60:1117-22. [ Links ]
10. Tager RE, Rikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. Rheumatology. 1999; 38:397-400. [ Links ]
11. Soer NA, Franks AG. Cutaneous manifestations of rheumatic diseases. In Kelley WN, Ruddy S, Harris Jr ED, Sledge CB. Textbook of Rheumatology. Philadelphia: WB Saunders; 1997. p.497-510. [ Links ]
12. Seibold J. Scleroderma. In Harris Jr, ED, Ruddy S, Sledge CTB. Kelley's Textbook of Rheumatology, Philadelphia: WB Saunders; 2005.p.1279-306. [ Links ]
13. Akensson A, Wolheim FA. Organ manifestation in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989; 28:281-6. [ Links ]
Thelma L. Skare
Rua João Alencar Guimarães, 796
80310420 - Curitiba - PR
Received on October 22, 2004.
Approved by the Consultive Council and accepted for publication on June 27, 2005.
* Work done at Service of Rheumatology, Hospital Universitário Evangélico de Curitiba (HUEC) - Curitiba (PR), Brazil.